Briefing
FDA authorizes clonoSEQ, the first NGS-based MRD test for multiple myeloma and B-cell ALL
On September 28, 2018, FDA granted De Novo authorization for Adaptive Biotechnologies' clonoSEQ assay to detect and monitor MRD in bone-marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia, with the agency describing detection of remaining cancer cells at very low levels (down to about 1 in 1,000,000 cells).
- Design: regulatory
- Assay: clonoSEQ NGS, bone marrow